1 active not recruiting, 1 recruiting, 1 terminated. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Undifferentiated Carcinoma: new trials by email Literature Review of Undifferentiated Carcinoma trials Research Report on Undifferentiated Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions organoid etablishment - Undifferentiated Carcinoma | Recruiting | Centre Francois Baclesse | 20 | 2025-03-05 | 2025-12-24 | |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1052 | 2007-12-06 | 2025-12-30 |
| Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck Abraxane, Erbitux, Carboplatin - Squamous Cell Carcinoma of the Head and Neck, Basaloid Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Dana-Farber Cancer Institute | 29 | 2007-11-01 | 2017-11-13 |
Carcinoma (3) · Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1) · Brenner Tumor (1) · Carcinoma, Adenosquamous (1) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms by Site (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Carcinoma, Squamous Cell (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1)
Carboplatin (2) · Paclitaxel (2) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Cetuximab (1) · Disulfides (1) · Docetaxel (1) · Gemcitabine (1) · Immunoglobulin G (1) · Radiotherapy, Intensity-Modulated (1) · Taxes (1)
Centre Francois Baclesse (1) · Dana-Farber Cancer Institute (1) · National Cancer Institute (NCI) (1)
France (1) · Japan (1) · South Korea (1) · United States (1)
Robert L Coleman (1) · Roy B. Tishler, MD (1)
PMID 28438473, PMID 31722153, PMID 37185961
U10CA027469 (1), U10CA180868 (1)